Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BWF2

UPID:
TRAIP_HUMAN

ALTERNATIVE NAMES:
RING finger protein 206; TRAF-interacting protein

ALTERNATIVE UPACC:
Q9BWF2; B5BU84; B5BUL3; O00467

BACKGROUND:
The E3 ubiquitin-protein ligase TRAIP is essential for genome integrity, mediating ubiquitination crucial for DNA repair mechanisms, including interstrand cross-link repair and covalent DNA-protein cross-link repair. It also influences the spindle assembly checkpoint and modulates innate immune responses. Its ubiquitination activity is vital for the proper functioning of cellular processes that preserve genomic stability.

THERAPEUTIC SIGNIFICANCE:
TRAIP's critical role in Seckel syndrome 9, characterized by severe growth and developmental anomalies, underscores its potential as a target for therapeutic development. Exploring the functions of E3 ubiquitin-protein ligase TRAIP could lead to innovative treatments for related genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.